Home › Funds › John Hancock › Health Sciences Trust
Fund family: John Hancock · Filed by JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 756913) · SEC series S000008239
Share classes and tickers: JAFKX (C000022444), JAFMX (C000022442), JEHSX (C000022443)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,299 with, 27 against, 16 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as John Hancock’s manager page (290,519 ballot items across 99 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | John Hancock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.0% | 1,242 | 90.1% | 242,172 |
| Backed environmental and social shareholder proposals at US companies | n/a | 8 | 13.4% | 1,935 |
Each ballot item this fund voted is set against the votes of the other John Hancock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most John Hancock funds on 145 items (13.7% of the 1,062 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most John Hancock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| CYTOKINETICS, INCORPORATED | 2026-05-27 | 2 wordings Election of Class I Directors for terms expiring in 2029. Edward M. Kaye, M.D. | Withhold | FOR — 10 of 10 John Hancock funds | Against | — |
| BIO-RAD LABORATORIES, INC. | 2026-04-21 | Nominees: Arnold A. Pinkston | Against | FOR — 8 of 8 John Hancock funds | Against | Passed (calculated), 88.8% support |
| BIO-RAD LABORATORIES, INC. | 2026-04-21 | Nominees: Melinda Litherland | Against | FOR — 8 of 8 John Hancock funds | Against | Passed (calculated), 88.3% support |
| RHYTHM PHARMACEUTICALS, INC. | 2026-06-24 | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. | For | AGAINST — 7 of 7 John Hancock funds | For | Approved, 81.5% support |
| MODERNA, INC. | 2026-05-06 | To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified or such director's earlier death, resignation or removal. Sandra H | For | AGAINST — 6 of 6 John Hancock funds | For | — |
| GUARDANT HEALTH, INC. | 2026-06-17 | Election of Class II Directors Ian Clark | For | WITHHOLD — 6 of 6 John Hancock funds | For | — |
| GUARDANT HEALTH, INC. | 2026-06-17 | Election of Class II Directors Manuel Hidalgo Medina | For | WITHHOLD — 6 of 6 John Hancock funds | For | — |
| IONIS PHARMACEUTICALS, INC. | 2026-06-04 | Election of Directors Joan E. Herman | Against | FOR — 6 of 6 John Hancock funds | Against | — |
| IONIS PHARMACEUTICALS, INC. | 2026-06-04 | Election of Directors Spencer R. Berthelsen | Against | FOR — 6 of 6 John Hancock funds | Against | — |
| ABBVIE INC. | 2026-05-08 | Shareholder Stockholder Proposal - to Adopt a Policy to Require an Independent Chair | Against | FOR — 9 of 10 John Hancock funds | For | Not approved, 39.6% support |
| ABBVIE INC. | 2026-05-08 | Election of Class II Directors Frederick H. Waddell | Against | FOR — 9 of 10 John Hancock funds | Against | — |
| ABBVIE INC. | 2026-05-08 | Election of Class II Directors Jennifer L. Davis | Against | FOR — 9 of 10 John Hancock funds | Against | — |
| ABBVIE INC. | 2026-05-08 | Election of Class II Directors Melody B. Meyer | Against | FOR — 9 of 10 John Hancock funds | Against | — |
| REGENERON PHARMACEUTICALS, INC. | 2026-06-12 | Election of Directors Christine A. Poon | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| REGENERON PHARMACEUTICALS, INC. | 2026-06-12 | Election of Directors Craig B. Thompson, M.D. | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| REGENERON PHARMACEUTICALS, INC. | 2026-06-12 | Election of Directors Joseph L. Goldstein, M.D. | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| NATERA, INC. | 2026-06-11 | DIRECTOR: Herm Rosenman* | Abstain | FOR — 5 of 5 John Hancock funds | Against | — |
| NATERA, INC. | 2026-06-11 | DIRECTOR: Jonathan Sheena* | Abstain | FOR — 5 of 5 John Hancock funds | Against | — |
| NATERA, INC. | 2026-06-11 | DIRECTOR: Rowan Chapman* | Abstain | FOR — 5 of 5 John Hancock funds | Against | — |
| INSMED INCORPORATED | 2026-05-13 | DIRECTOR: C. Desjardins, Ph.D. | Abstain | FOR — 5 of 5 John Hancock funds | Against | — |
| REPLIGEN CORPORATION | 2026-05-14 | Election of Directors Carrie Eglinton Manner | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| REPLIGEN CORPORATION | 2026-05-14 | Election of Directors Glenn P. Muir | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| MADRIGAL PHARMACEUTICALS INC. | 2026-06-17 | 2 wordings Re-election of Class I directors: Julian Baker | Withhold | FOR — 5 of 5 John Hancock funds | Against | Elected, 88.6% support |
| KRYSTAL BIOTECH, INC. | 2026-05-15 | DIRECTOR: Christopher Mason | For | ABSTAIN — 5 of 5 John Hancock funds | For | — |
| KRYSTAL BIOTECH, INC. | 2026-05-15 | DIRECTOR: Krish S. Krishnan | For | ABSTAIN — 5 of 5 John Hancock funds | For | — |
| Company | Meeting | Item | This fund | Most John Hancock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | 2026-06-24 | DIRECTOR: David W.J. McGirr | For | ABSTAIN — 5 of 5 John Hancock funds | For | — |
| DENALI THERAPEUTICS INC. | 2026-06-03 | DIRECTOR: David Schenkein, M.D. | For | ABSTAIN — 5 of 5 John Hancock funds | For | — |
| DENALI THERAPEUTICS INC. | 2026-06-03 | DIRECTOR: Jennifer Cook | For | ABSTAIN — 5 of 5 John Hancock funds | For | — |
| STOKE THERAPEUTICS, INC. | 2026-06-03 | To approve, on an advisory basis, the compensation of the Company's named executive officers. | For | AGAINST — 5 of 5 John Hancock funds | For | Passed (calculated), 72.9% support |
| OCULAR THERAPEUTIX, INC. | 2026-06-10 | To approve an advisory vote on named executive officer compensation. | For | AGAINST — 5 of 5 John Hancock funds | For | — |
| PROCEPT BIOROBOTICS CORPORATION | 2026-06-09 | Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. | For | AGAINST — 5 of 5 John Hancock funds | For | Approved, 73.1% support |
| MOLINA HEALTHCARE, INC. | 2026-05-06 | To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. | For | AGAINST — 10 of 12 John Hancock funds | For | Passed (calculated), 52.8% support |
| BRIGHTSPRING HEALTH SERVICES, INC. | 2026-05-21 | 2 wordings Election of Class II directors Olivia Kirtley | For | WITHHOLD — 7 of 8 John Hancock funds | For | — |
| REVVITY, INC. | 2026-04-28 | Shareholder To approve the shareholder proposal regarding Executives to Retain Significant Stock. | Against | FOR — 9 of 11 John Hancock funds | For | Failed (calculated), 23.1% support |
| ROIVANT SCIENCES LTD. | 2025-09-10 | DIRECTOR: Keith Manchester | For | ABSTAIN — 4 of 4 John Hancock funds | For | — |
| ROIVANT SCIENCES LTD. | 2025-09-10 | DIRECTOR: Matthew Gline | For | ABSTAIN — 4 of 4 John Hancock funds | For | — |
| ROIVANT SCIENCES LTD. | 2025-09-10 | DIRECTOR: Melissa Epperly | For | ABSTAIN — 4 of 4 John Hancock funds | For | — |
| CELCUITY INC. | 2026-05-14 | DIRECTOR: Leo T. Furcht | Abstain | FOR — 4 of 4 John Hancock funds | Against | — |
| MONTE ROSA THERAPEUTICS, INC. | 2026-06-11 | To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; Anthony Manning, Ph.D. | For | WITHHOLD — 4 of 4 John Hancock funds | For | — |
| BRIDGEBIO PHARMA, INC. | 2026-06-22 | DIRECTOR: Hannah A. Valantine, MD | For | ABSTAIN — 6 of 7 John Hancock funds | For | — |
| BRIDGEBIO PHARMA, INC. | 2026-06-22 | To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares. | For | AGAINST — 6 of 7 John Hancock funds | For | Approved, 82.9% support |
| ELI LILLY AND COMPANY | 2026-05-04 | Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. | Against | FOR — 9 of 12 John Hancock funds | For | Not approved, 33.7% support |
| MOLINA HEALTHCARE, INC. | 2026-05-06 | To consider and approve an amendment to the Company's 2025 Equity Incentive Plan to increase the number of shares available for issuance under such plan. | For | AGAINST — 7 of 9 John Hancock funds | For | Passed (calculated), 73.5% support |
| BOSTON SCIENTIFIC CORPORATION | 2026-04-30 | Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." | Against | FOR — 5 of 6 John Hancock funds | For | Not approved, 42.8% support |
| ZOETIS INC. | 2026-05-20 | Shareholder Shareholder proposal to permit shareholder action by written consent. | Against | FOR — 5 of 6 John Hancock funds | For | — |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Mahkam Zanganeh | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Manmeet S. Soni | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Robert W. Duggan | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| SUMMIT THERAPEUTICS INC. | 2026-06-10 | DIRECTOR: Yu (Michelle) Xia | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| PRAXIS PRECISION MEDICINES, INC. | 2026-06-10 | To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified. William Young | For | WITHHOLD — 5 of 6 John Hancock funds | For | — |
| MIRUM PHARMACEUTICALS, INC. | 2026-06-15 | To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Lon Cardon, Ph.D., FMedSci | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| MIRUM PHARMACEUTICALS, INC. | 2026-06-15 | To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Timothy Walbert | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| MIRUM PHARMACEUTICALS, INC. | 2026-06-15 | To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. William Fairey | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| KODIAK SCIENCES INC. | 2026-06-02 | Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. Bancroft | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| LIQUIDIA CORPORATION | 2026-06-16 | Election of Directors: Katie Rielly-Gauvin | For | WITHHOLD — 3 of 3 John Hancock funds | For | Passed (calculated), 92.2% support |
| LIQUIDIA CORPORATION | 2026-06-16 | Election of Directors: Ramandeep Singh | For | WITHHOLD — 3 of 3 John Hancock funds | For | Passed (calculated), 91.6% support |
| RELAY THERAPEUTICS, INC. | 2026-06-09 | To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Claire Mazumdar, Ph.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| RELAY THERAPEUTICS, INC. | 2026-06-09 | To elect two class III directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal; Douglas S. Ingram | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| TANGO THERAPEUTICS, INC. | 2026-06-04 | Election of Class II Directors Kanishka Pothula | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| TANGO THERAPEUTICS, INC. | 2026-06-04 | Election of Class II Directors Mace Rothenberg, M.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| TANGO THERAPEUTICS, INC. | 2026-06-04 | Election of Class II Directors Malte Peters, M.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| IOVANCE BIOTHERAPEUTICS, INC. | 2026-06-10 | To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6. | Against | FOR — 3 of 3 John Hancock funds | Against | — |
| TARSUS PHARMACEUTICALS, INC. | 2026-06-25 | To elect Class III directors, to serve until the 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. Andrew Goldberg | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ENLIVEN THERAPEUTICS, INC. | 2026-06-09 | To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Lori Kunkel, M.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| IDEAYA BIOSCIENCES, INC. | 2026-06-16 | To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected; M. Garret Hampton, Ph.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| BEAM THERAPEUTICS INC. | 2026-06-03 | Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. Christi Shaw | For | AGAINST — 3 of 3 John Hancock funds | For | — |
| BEAM THERAPEUTICS INC. | 2026-06-03 | Election of the following nominees as Class III directors for three-year terms ending at our Annual Meeting of Stockholders to be held in 2029. John Maraganore, Ph.D. | For | AGAINST — 3 of 3 John Hancock funds | For | — |
| XENCOR, INC. | 2026-06-16 | Approval of the amendment to the Company's Amended and Restated 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 4,000,000 shares; and | For | AGAINST — 3 of 3 John Hancock funds | For | Approved, 82.0% support |
| PALVELLA THERAPEUTICS, INC | 2026-06-10 | Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares. | For | AGAINST — 3 of 3 John Hancock funds | For | — |
| PALVELLA THERAPEUTICS, INC | 2026-06-10 | Election of three director nominees to serve as Class III directors whose term will expire in 2029. Todd C. Davis | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| VERA THERAPEUTICS, INC. | 2026-05-21 | DIRECTOR: Michael M Morrissey PhD | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| BIOHAVEN LTD | 2026-04-28 | Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Irina Antonijevic, M.D., Ph.D. | For | AGAINST — 3 of 3 John Hancock funds | For | Elected, 84.0% support |
| BIOHAVEN LTD | 2026-04-28 | Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Michael T. Heffernan | For | AGAINST — 3 of 3 John Hancock funds | For | Elected, 83.5% support |
| BIOHAVEN LTD | 2026-04-28 | Election of Directors for a term expiring at the 2029 Annual Meeting of shareholders: Robert J. Hugin | For | AGAINST — 3 of 3 John Hancock funds | For | Elected, 84.0% support |
| STOKE THERAPEUTICS, INC. | 2026-06-03 | DIRECTOR: Adrian Krainer, Ph.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| NURIX THERAPEUTICS, INC. | 2026-05-15 | DIRECTOR: Arthur T. Sands, M.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| NURIX THERAPEUTICS, INC. | 2026-05-15 | DIRECTOR: Paul M. Silva | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| ULTRAGENYX PHARMACEUTICAL INC. | 2026-05-14 | Approval of the Third Amended and Restated 2023 Incentive Plan. | For | AGAINST — 3 of 3 John Hancock funds | For | Approved, 68.9% support |
| NUVATION BIO INC. | 2026-05-21 | DIRECTOR: Robert Bazemore | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| NUVATION BIO INC. | 2026-05-21 | DIRECTOR: Robert Mashal, M.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| TYRA BIOSCIENCES, INC. | 2026-05-28 | To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified. Robert More | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| OCULAR THERAPEUTIX, INC. | 2026-06-10 | DIRECTOR: Merilee Raines | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| OCULAR THERAPEUTIX, INC. | 2026-06-10 | DIRECTOR: Pravin U. Dugel, M.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| RAPPORT THERAPEUTICS, INC. | 2026-06-10 | DIRECTOR: Robert J. Perez | For | ABSTAIN — 3 of 3 John Hancock funds | For | Passed (calculated), 88.8% support |
| PROCEPT BIOROBOTICS CORPORATION | 2026-06-09 | 2 wordings Election of Class II directors to serve until 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Antal Desai | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ORIC PHARMACEUTICALS, INC. | 2026-06-18 | To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. Mardi C. Dier | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ALUMIS INC | 2026-06-30 | DIRECTOR: Zhengbin Yao, Ph.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| CULLINAN THERAPEUTICS, INC. | 2026-06-16 | DIRECTOR: Nadim Ahmed | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| CULLINAN THERAPEUTICS, INC. | 2026-06-16 | DIRECTOR: Stephen Webster | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| OLEMA PHARMACEUTICALS, INC. | 2026-06-17 | DIRECTOR: Yi Larson | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| ALLOGENE THERAPEUTICS, INC. | 2026-06-18 | Election of Directors Deborah Messemer | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ALLOGENE THERAPEUTICS, INC. | 2026-06-18 | Election of Directors Owen Witte, M.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ALLOGENE THERAPEUTICS, INC. | 2026-06-18 | Election of Directors Vicki Sato, Ph.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ROCKET PHARMACEUTICALS, INC. | 2026-05-20 | The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal; Peter Fong, Ph.D. | Withhold | FOR — 3 of 3 John Hancock funds | Against | — |
| AURA BIOSCIENCES, INC. | 2026-06-11 | DIRECTOR: David Johnson | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| BEONE MEDICINES AG | 2026-06-11 | THAT MS. SHALINI SHARP BE AND IS HEREBY RE-ELECTED TO SERVE AS A DIRECTOR OF THE COMPANY FOR A TERM EXTENDING UNTIL COMPLETION OF THE 2027 ANNUAL GENERAL MEETING | Against | FOR — 3 of 3 John Hancock funds | Against | — |
| BETA BIONICS, INC. | 2026-05-21 | To elect two Class I directors, as nominated by the Board of Directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Christy Jones | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ENTRADA THERAPEUTICS, INC. | 2026-06-10 | Election of Directors Bernhardt Zeiher, M.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| ENTRADA THERAPEUTICS, INC. | 2026-06-10 | Election of Directors Peter S. Kim, Ph.D. | For | WITHHOLD — 3 of 3 John Hancock funds | For | — |
| SIONNA THERAPEUTICS, INC. | 2026-06-17 | DIRECTOR: Marcella K. Ruddy, MD | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| SIONNA THERAPEUTICS, INC. | 2026-06-17 | DIRECTOR: Peter A. Thompson, M.D. | For | ABSTAIN — 3 of 3 John Hancock funds | For | — |
| STRYKER CORPORATION | 2026-05-06 | Election of Directors. Emmanuel P. Maceda | For | AGAINST — 6 of 8 John Hancock funds | For | — |
| WATERS CORPORATION | 2026-01-27 | Approve adjourning the Special Meeting, if necessary, (a) to solicit additional proxies if there are insufficient votes to approve the Share Issuance Proposal, (b) if insufficient shares of Waters Common Stock are represented (online or by proxy) to conduct business at the Special Meeting, and (c) t | Against | FOR — 6 of 8 John Hancock funds | Against | — |
| CYTOKINETICS, INCORPORATED | 2026-05-27 | Election of Class I Directors for terms expiring in 2029. Wendell Wierenga, Ph.D. | Withhold | FOR — 7 of 10 John Hancock funds | Against | — |
| VERTEX PHARMACEUTICALS INCORPORATED | 2026-05-13 | Shareholder Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. | Against | FOR — 4 of 5 John Hancock funds | For | Approved, 57.0% support |
| HCA HEALTHCARE, INC. | 2026-04-23 | Shareholder Stockholder proposal, if properly presented at the meeting, regarding shareholders' right to act by written consent. | Against | FOR — 4 of 5 John Hancock funds | For | — |
| IDEXX LABORATORIES, INC. | 2026-05-12 | Shareholder Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). | Against | FOR — 4 of 5 John Hancock funds | For | — |
| PROTAGONIST THERAPEUTICS, INC. | 2026-06-17 | DIRECTOR: Dinesh V. Patel, Ph.D. | For | ABSTAIN — 4 of 5 John Hancock funds | For | — |
| PROTAGONIST THERAPEUTICS, INC. | 2026-06-17 | To approve the adoption of the Company's 2026 Equity Incentive Plan. | For | AGAINST — 4 of 5 John Hancock funds | For | Approved, 84.4% support |
| CRINETICS PHARMACEUTICALS, INC. | 2026-06-18 | To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Caren Deardorf | For | WITHHOLD — 4 of 5 John Hancock funds | For | — |
| CRINETICS PHARMACEUTICALS, INC. | 2026-06-18 | To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Stephanie S. Okey, M.S. | For | WITHHOLD — 4 of 5 John Hancock funds | For | — |
| NUVALENT, INC. | 2026-06-16 | Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D. | For | WITHHOLD — 4 of 5 John Hancock funds | For | Elected, 81.5% support |
| ALNYLAM PHARMACEUTICALS, INC. | 2026-05-20 | To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D. | Against | FOR — 5 of 7 John Hancock funds | Against | Elected, 89.3% support |
| THE CIGNA GROUP | 2026-04-22 | Shareholder Shareholder Proposal - Shareholder Right to Act by Written Consent | Against | FOR — 6 of 9 John Hancock funds | For | Failed (calculated), 47.9% support |
| REVOLUTION MEDICINES, INC. | 2026-06-18 | DIRECTOR: Alexis Borisy | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| WEST PHARMACEUTICAL SERVICES, INC. | 2026-05-04 | Shareholder Shareholder proposal regarding an independent Board Chair policy. | Against | FOR — 4 of 6 John Hancock funds | For | Not approved, 46.4% support |
| SPYRE THERAPEUTICS INC. | 2026-05-27 | DIRECTOR: Laurie Stelzer | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| SCHOLAR ROCK HOLDING CORPORATION | 2026-06-04 | DIRECTOR: David Hallal | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| SCHOLAR ROCK HOLDING CORPORATION | 2026-06-04 | DIRECTOR: Katie Peng | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| SCHOLAR ROCK HOLDING CORPORATION | 2026-06-04 | DIRECTOR: Kristina Burow | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| SCHOLAR ROCK HOLDING CORPORATION | 2026-06-04 | DIRECTOR: Michael Gilman | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| COGENT BIOSCIENCES, INC. | 2026-06-09 | DIRECTOR: Arlene M. Morris | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| COGENT BIOSCIENCES, INC. | 2026-06-09 | DIRECTOR: Dr. Chris Cain | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| COGENT BIOSCIENCES, INC. | 2026-06-09 | DIRECTOR: Todd Shegog | For | ABSTAIN — 3 of 4 John Hancock funds | For | — |
| DIANTHUS THERAPEUTICS, INC. | 2026-05-21 | To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| DISC MEDICINE, INC. | 2026-06-18 | To elect each of the following Class III nominees to the Board of Directors as set forth below: Donald Nicholson, Ph.D. | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| MBX BIOSCIENCES | 2026-06-04 | Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. Mathers | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| MBX BIOSCIENCES | 2026-06-04 | Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. Heron | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| IMMUNOME INC. | 2026-06-09 | To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal. James Boylan | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| BICARA THERAPEUTICS INC. | 2026-06-09 | To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Carolyn Ng, Ph.D. | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| BICARA THERAPEUTICS INC. | 2026-06-09 | To elect two class II directors to our board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Christopher Bowden, M.D. | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| MAPLIGHT THERAPEUTICS, INC. | 2026-06-23 | To elect the three Class I Director nominees named in the Proxy Statement to serve until the 2029 annual meeting of our stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. George Pavlov | For | WITHHOLD — 3 of 4 John Hancock funds | For | — |
| CVS HEALTH CORPORATION | 2026-05-14 | Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. | Against | FOR — 6 of 11 John Hancock funds | For | — |
| UNITED THERAPEUTICS CORPORATION | 2026-06-26 | Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan. | For | AGAINST — 5 of 9 John Hancock funds | For | Passed (calculated), 72.0% support |
| VAXCYTE, INC. | 2026-06-15 | DIRECTOR: Halley Gilbert, J.D. | For | ABSTAIN — 5 of 9 John Hancock funds | For | — |
| VAXCYTE, INC. | 2026-06-15 | DIRECTOR: Olivier Brandicourt MD | For | ABSTAIN — 5 of 9 John Hancock funds | For | — |
| KYMERA THERAPEUTICS, INC. | 2026-06-24 | DIRECTOR: Bruce Booth, D.Phil. | For | ABSTAIN — 4 of 7 John Hancock funds | For | — |
| KYMERA THERAPEUTICS, INC. | 2026-06-24 | DIRECTOR: Elena Ridloff, CFA | For | ABSTAIN — 4 of 7 John Hancock funds | For | — |
| KYMERA THERAPEUTICS, INC. | 2026-06-24 | DIRECTOR: John Maraganore, Ph.D. | For | ABSTAIN — 4 of 7 John Hancock funds | For | — |
| KYMERA THERAPEUTICS, INC. | 2026-06-24 | DIRECTOR: Nello Mainolfi, Ph.D. | For | ABSTAIN — 4 of 7 John Hancock funds | For | — |
| NATERA, INC. | 2026-06-11 | To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated. | For | AGAINST — 3 of 5 John Hancock funds | For | Passed (calculated), 78.1% support |
| REPLIGEN CORPORATION | 2026-05-14 | Election of Directors Karen A. Dawes | For | AGAINST — 3 of 5 John Hancock funds | For | — |
| ROYALTY PHARMA PLC | 2026-06-04 | Election of Directors David Hodgson | For | AGAINST — 2 of 3 John Hancock funds | For | — |
| ROYALTY PHARMA PLC | 2026-06-04 | Election of Directors Pablo Legorreta | For | AGAINST — 2 of 3 John Hancock funds | For | — |
| BEONE MEDICINES AG | 2026-06-11 | THAT MR. JOHN V. OYLER BE AND IS HEREBY RE-ELECTED TO SERVE AS CHAIRMAN OF THE BOARD OF DIRECTORS OF THE COMPANY FOR A TERM EXTENDING UNTIL COMPLETION OF THE 2027 ANNUAL GENERAL MEETING | For | AGAINST — 2 of 3 John Hancock funds | For | — |
Download all 145 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 75.9% of this fund’s 1,342 such votes could be given a sector; the other 324 (24.1%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 952 | 23 | 2.4% |
| Industrials | 49 | 2 | 4.1% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 798 | 0 |
| Audit-related | 159 | 0 |
| Say-on-Pay | 147 | 0 |
| Capital Structure | 83 | 1 |
| Compensation | 75 | 1 |
| Corporate Governance | 60 | 16 |
| Other | 22 | 0 |
| Other Social Issues | 7 | 3 |
| Human Rights or Human Capital/workforce | 5 | 5 |
| Shareholder Rights and Defenses | 4 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| ELI LILLY AND COMPANY | May 4, 2026 | $39M | 10 | 2 |
| ABIVAX SA | May 11, 2026 | $26M | 2 | 0 |
| THERMO FISHER SCIENTIFIC INC. | May 20, 2026 | $13M | 13 | 0 |
| ARGENX SE | November 18, 2025 | $13M | 1 | 0 |
| UNITEDHEALTH GROUP INCORPORATED | June 1, 2026 | $11M | 12 | 1 |
| MERCK & CO., INC. | May 26, 2026 | $9M | 18 | 3 |
| ABBVIE INC. | May 8, 2026 | $9M | 8 | 1 |
| ARGENX SE | May 6, 2026 | $9M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | ELI LILLY AND COMPANY | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| June 1, 2026 | UNITEDHEALTH GROUP INCORPORATED | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 8, 2026 | ABBVIE INC. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | GILEAD SCIENCES, INC. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 19, 2026 | AMGEN INC. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 14, 2026 | CVS HEALTH CORPORATION | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| May 13, 2026 | ELEVANCE HEALTH, INC. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
1,362 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Health Sciences Trust (JAFKX) voted at 160 shareholder meetings of 157 companies, on 1,362 ballot items in all. Where management made a recommendation, the fund followed it on 96.8% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals more often than John Hancock's funds as a whole (92.0% against 90.1%). It voted differently from most John Hancock funds on 145 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of John Hancock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.